Brammer Bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Brammer Bio's estimated annual revenue is currently $21.1M per year.(i)
  • Brammer Bio's estimated revenue per employee is $201,000

Employee Data

  • Brammer Bio has 105 Employees.(i)
  • Brammer Bio grew their employee count by -49% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-49%$10.5MN/A

Brammer Bio is a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies. Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts. Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. The Brammer team consists of extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients. We are Helping to Cure.® The management team is led by President and CEO Mark Bamforth; Chief Scientific Officer Dr. Richard Snyder, the founder of Florida Biologix, which was spun out of the University of Florida in 2015; and Chief Operating Officer Christopher Murphy. Brammer Bio offers a competitive benefits package, including medical, dental, vision, paid time off, holidays, 401(k) with a company match, incentive bonus, flexible spending account (FSA), and educational assistance.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

105

Number of Employees

$21.1M

Revenue (est)

-49%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Brammer Bio News

2022-04-17 - Viral Vector Manufacturing Market Size And Forecast | Novasep ...

Novasep, Brammer Bio, Lonza, Cobra Biologics, Oxford Biomedica, Finvector Vision Therapies, Merck KGaA, Spark Therapeutics, uniQure, Merck.

2022-04-17 - Why Viral Vector and Plasmid Manufacturing Market May See ...

... Market May See Potentially High Growth Factors, Explore by Top Players Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult.

2022-04-17 - Viral Vector Vaccines Market Size And Forecast | Advanced ...

KG, Brammer Bio, LLC, Creative Biogene, GE Healthcare, Pfizer Inc. and Sanofi S.A.. The report provides a good overview of the key...

2019-09-06 - “Global Viral Vector Development Service Market 2019 ...

“Global Viral Vector Development Service Market 2019 – Kaneka Eurogentec , FinVector , Brammer Bio , Cell and Gene rapy Catapult “.

2019-09-06 - Manufacturing market for viral vectors and plasmids set to boom

Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.1M105-9%N/A
#2
$14.4M106960%N/A
#3
$21.7M10618%N/A
#4
$22.4M1076%N/A
#5
$7.5M10722%N/A